A detailed history of Vanguard Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,946,536 shares of SMMT stock, worth $202 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,946,536
Previous 8,818,463 24.13%
Holding current value
$202 Million
Previous $68.8 Million 248.52%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.89 - $31.93 $14.7 Million - $67.9 Million
2,128,073 Added 24.13%
10,946,536 $240 Million
Q2 2024

Aug 13, 2024

BUY
$2.39 - $10.92 $3.7 Million - $16.9 Million
1,549,220 Added 21.31%
8,818,463 $68.8 Million
Q1 2024

May 10, 2024

BUY
$2.55 - $5.07 $648,365 - $1.29 Million
254,261 Added 3.62%
7,269,243 $30.1 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.83 $1.54 Million - $2.6 Million
919,307 Added 15.08%
7,014,982 $18.3 Million
Q3 2023

Nov 14, 2023

SELL
$1.54 - $2.42 $7,415 - $11,652
-4,815 Reduced 0.08%
6,095,675 $11.4 Million
Q2 2023

Aug 14, 2023

BUY
$1.32 - $2.81 $6.12 Million - $13 Million
4,635,361 Added 316.38%
6,100,490 $15.3 Million
Q1 2023

May 15, 2023

BUY
$1.38 - $5.41 $29,767 - $116,699
21,571 Added 1.49%
1,465,129 $2.56 Million
Q4 2022

Feb 10, 2023

BUY
$0.68 - $5.31 $453,992 - $3.55 Million
667,636 Added 86.04%
1,443,558 $6.14 Million
Q2 2022

Aug 12, 2022

SELL
$0.92 - $2.38 $124,636 - $322,428
-135,474 Reduced 14.86%
775,922 $776,000
Q1 2022

May 13, 2022

BUY
$2.0 - $3.45 $9,018 - $15,556
4,509 Added 0.5%
911,396 $2.23 Million
Q4 2021

Feb 14, 2022

BUY
$2.45 - $5.64 $3,324 - $7,653
1,357 Added 0.15%
906,887 $2.44 Million
Q3 2021

Nov 12, 2021

BUY
$4.83 - $8.27 $123,802 - $211,976
25,632 Added 2.91%
905,530 $4.54 Million
Q2 2021

Aug 13, 2021

BUY
$5.15 - $8.46 $4.53 Million - $7.44 Million
879,898 New
879,898 $6.56 Million

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.72B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.